NeoGenomics Stock Forecast for 2023 - 2025 - 2030
Updated on 03/28/2024
NeoGenomics Stock Forecast and Price Target
The average price target for NeoGenomics's stock lately set by several renowned analysts is $20.00, which would result in a potential upside of approximately 25.55% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of $30.00 and a low estimate of $18.00. If you are looking to invest in the stock, it's important to research and compare different companies.
25.55% Upside
NeoGenomics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, NeoGenomics's Price has fallen from $7.02 to $0.00 – a 100.00% decrease. For next year, analysts predict Fair Value of $17.28, which would mean an increase of 100.00%. Over the next seven years, experts predict that NeoGenomics's Fair Value will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$599.43 | Buy/Sell | $591.94 | 0.10% |
ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF242.00 | Buy/Sell | CHF307.83 | 11.57% |
ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$120.19 | Buy/Sell | $118.92 | 4.83% |
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
ILMN Stock Forecast | Illumina | Outperform |
16
|
$139.06 | Buy/Sell | $159.28 | 7.87% |
NeoGenomics Revenue Forecast for 2023 - 2025 - 2030
In the last three years, NeoGenomics's Revenue has grown by 33.12%, rising from $444.45M to $591.64M. For next year, analysts predict Revenue of $633.52M, which would mean an increase of 7.08%. Over the next seven years, experts predict that NeoGenomics's Revenue will grow at a rate of 19.72%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$218.53 | Buy/Sell | $241.28 | 11.20% |
HOLX Stock Forecast | Hologic | Outperform |
8
|
$76.33 | Buy/Sell | $81.06 | 7.56% |
DGX Stock Forecast | Quest Diagnostics | Outperform |
10
|
$129.43 | Buy/Sell | $141.17 | 9.94% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
6869 Stock Forecast | Sysmex | Outperform |
18
|
¥7.99k | Buy/Sell | ¥8.90k | 11.40% |
EXAS Stock Forecast | Exact Sciences | Buy |
8
|
$60.70 | Buy/Sell | $90.32 | 44.98% |
NTRA Stock Forecast | Natera | Outperform |
7
|
$89.28 | Buy/Sell | $74.41 | 6.41% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
QGEN Stock Forecast | QIAGEN N.V. | Outperform |
15
|
$45.02 | Buy/Sell | $0.00 | 11.57% |
SHL Stock Forecast | Sonic Healthcare | Hold |
18
|
$28.47 | Buy/Sell | $34.12 | 8.89% |
GH Stock Forecast | Guardant Health | Buy |
6
|
$18.99 | Buy/Sell | $43.00 | 136.97% |
NeoGenomics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, NeoGenomics's EBITDA has gone down from $23.80M to $-24.07M – a 201.13% drop. In the next year, 11 analysts estimate that NeoGenomics's EBITDA will decrease by 173.66%, reaching $17.73M. For the next seven years, experts predict that NeoGenomics's EBITDA will grow at a rate of 1624.89%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MYGN Stock Forecast | Myriad Genetics | Hold |
6
|
$22.58 | Buy/Sell | $22.08 | 10.72% |
VCYT Stock Forecast | Veracyte | Outperform |
11
|
$22.66 | Buy/Sell | $32.17 | 43.42% |
OPK Stock Forecast | OPKO Health | Outperform |
8
|
$1.01 | Buy/Sell | $6.70 | 296.04% |
NeoGenomics EBIT Forecast for 2023 - 2025 - 2030
NeoGenomics's EBIT has seen impressive growth In the last three years, rising from $-11.92M to $-96.65M – a growth of 710.82%. According to 11 analysts, NeoGenomics's EBIT will fall by 13.69% in the next year, reaching $-83.42M. Professionals believe that By 2030, NeoGenomics's EBIT will fall to $-68.97M – a 28.64% decrease from its current value.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
FLGT Stock Forecast | Fulgent Genetics | Hold |
16
|
$22.91 | Buy/Sell | $31.50 | 9.12% |
ADPT Stock Forecast | Adaptive Biotechnologies | Outperform |
6
|
$3.78 | Buy/Sell | $8.67 | 71.96% |
CDNA Stock Forecast | CareDx, Inc | Outperform |
9
|
$11.31 | Buy/Sell | $11.80 | 6.10% |
NeoGenomics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, NeoGenomics's EPS has fallen from $0.15 to $0.00 – a 100.00% decrease. For next year, analysts predict EPS of $-0.11, which would mean an increase of 100.00%. Over the next seven years, experts predict that NeoGenomics's EPS will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
A038290 Stock Forecast | Macrogen | Buy |
11
|
₩22.15k | Buy/Sell | ₩30.00k | 35.44% |
ATOS Stock Forecast | Atossa Genetics Inc | Buy |
5
|
$1.20 | Buy/Sell | $4.83 | 233.33% |
CRDF Stock Forecast | Cardiff Oncology | Buy |
10
|
$4.04 | Buy/Sell | $8.37 | 114.85% |